Experts recommend that clinicians clearly outline the areas of uncertainty pertaining to risk of harm from amyloid–targeting monoclonal antibodies when they counsel patients considering treatment.
Compared with patients receiving thin liquids, patients receiving thick liquids were less likely to be intubated, but more likely to have respiratory complications (eg, pneumonia).
Antiamyloid agents removing fibrillar amyloid plaques demonstrated effects on glial and postsynaptic fluid biomarkers downstream of initial amyloid deposition.
Probing Molecular Pathways: Illuminating the Connection Between COVID-19 and Alzheimer's Disease Through the Endocannabinoid System Dynamics
Source : https://pubmed.ncbi.nlm.nih.gov/38619024/
Our study investigates the molecular link between COVID-19 and Alzheimer's disease (AD). We aim to elucidate the mechanisms by which COVID-19 may influence the onset or progression of AD. Using...
These findings reveal a potential pathogenetic link between COVID-19 and Alzheimer disease, mediated by common differentially expressed genes and the endocannabinoid system pathway.
Traumatic Brain Injury and Post-Traumatic Stress Disorder and Their Influence on Development and Pattern of Alzheimer's Disease Pathology in Later Life
Source : https://pubmed.ncbi.nlm.nih.gov/38552112/
These findings suggest that a) although subsets of patients with PTSD and/or TBI develop AD-pathology, a history of TBI or PTSD alone or both is not associated with a significantly...
Although subsets of patients with PTSD and/or TBI develop Alzheimer disease pathology, a history of TBI or PTSD alone or both is not associated with a significantly higher risk of developing Alzheimer disease later in life.